Identification of differentially expressed genes in non-small cell lung cancer

Wang, Ke; Chen, Ruo; Feng, Zhuan; Zhu, Yumeng; Sun, Xiuxuan; Huang, Wan; Chen, Zhinan

doi:10.18632/aging.102521

Cited by 28 publications

(22 citation statements)

References 39 publications

(37 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Differences of the expression levels of CXCRs between AML patients and normal tissues were obtained from the GEPIA website ( ). the Gene Expression Profiling Interactive Analysis server (GEPIA) is a newly developed interactive web server ( 17 ) for analyzing the RNA sequencing expression data of thousands of tumor and normal samples from the TCGA and the GTEx projects using a standard processing pipeline ( 18 ). Since AML samples from TCGA database were all tumor samples, GEPIA matches normal samples from the GTEs database.…”

Section: Methodsmentioning

confidence: 99%

Risk Stratification in Acute Myeloid Leukemia Using CXCR Gene Signatures: A Bioinformatics Analysis

Zhu

Chen

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

The role of CXC chemokine receptors in tumors has been an increasingly researched focus in recent years. However, significant prognostic values of CXCR members in acute myeloid leukemia are yet to be explored profoundly. In this study, we firstly made an analysis of the relationship of CXCR family members and AML using samples from TCGA. Our results suggested that transcriptional expressions of CXCRs serve an important role in AML. CXCR transcript expressions, except CXCR1 expression, were significantly increased in AML. It displayed the expression pattern of CXCR members in different AML subtypes according to FAB classification. The correlations of CXCR transcript expression with different genotypes and karyotypes were also present. High CXCR2 expression was found to have a significantly worse prognosis compared with that of low CXCR2 expression, and CXCR2 was also found to be an independent prognostic factor. We also established a CXCR signature to identify high-risk subgroups of patients with AML. It was an independent prognostic factor and could become a powerful method to predict the survival rate of patients.

show abstract

Section: Methodsmentioning

confidence: 99%

Risk Stratification in Acute Myeloid Leukemia Using CXCR Gene Signatures: A Bioinformatics Analysis

Zhu

Chen

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…The tests were performed according to the previous methods. 38 The primer sequences were listed as follows: Human CD147-Forward: 5′-GACGACCAGTGGGGAGAGTA-3′ Human CD147-Reverse: 5′-GGCCTTGTCCTCAGAGTCAG-3′ Monkey CD147-Forward: 5′-GGCTCGAAGACACTCCTCAC-3′ Monkey CD147-Reverse: 5′-GAGTACTCTCCCCCGAGGTC-3′ Human/monkey ACE2-Forward: 5′-GTGCACAAAGGTGACAATGG-3′ Human/monkey ACE2-Reverse: 5′-GGCTGCAGAAAGTGACATGA-3′ Human/monkey GAPDH-Forward: 5′-GCACCGTCAAGGCTGAGA AC-3′…”

Section: Rna Extraction and Real-time Pcr Analysismentioning

confidence: 99%

CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells

Wang

Chen²,

Zhang

et al. 2020

Sig Transduct Target Ther

Self Cite

910

856

View full text Add to dashboard Cite

In face of the everlasting battle toward COVID-19 and the rapid evolution of SARS-CoV-2, no specific and effective drugs for treating this disease have been reported until today. Angiotensin-converting enzyme 2 (ACE2), a receptor of SARS-CoV-2, mediates the virus infection by binding to spike protein. Although ACE2 is expressed in the lung, kidney, and intestine, its expressing levels are rather low, especially in the lung. Considering the great infectivity of COVID-19, we speculate that SARS-CoV-2 may depend on other routes to facilitate its infection. Here, we first discover an interaction between host cell receptor CD147 and SARS-CoV-2 spike protein. The loss of CD147 or blocking CD147 in Vero E6 and BEAS-2B cell lines by anti-CD147 antibody, Meplazumab, inhibits SARS-CoV-2 amplification. Expression of human CD147 allows virus entry into non-susceptible BHK-21 cells, which can be neutralized by CD147 extracellular fragment. Viral loads are detectable in the lungs of human CD147 (hCD147) mice infected with SARS-CoV-2, but not in those of virus-infected wild type mice. Interestingly, virions are observed in lymphocytes of lung tissue from a COVID-19 patient. Human T cells with a property of ACE2 natural deficiency can be infected with SARS-CoV-2 pseudovirus in a dose-dependent manner, which is specifically inhibited by Meplazumab. Furthermore, CD147 mediates virus entering host cells by endocytosis. Together, our study reveals a novel virus entry route, CD147-spike protein, which provides an important target for developing specific and effective drug against COVID-19.

show abstract

“…It has been shown that multiple genes can be used as potential biomarkers for the diagnosis and prognosis of lung cancer ( 54 , 55 ). However, to the best of our knowledge, there are currently limited studies available on the effective molecular diagnostic markers of LUAD and LUSC.…”

Section: Discussionmentioning

confidence: 99%

Use of four genes in exosomes as biomarkers for the identification of lung adenocarcinoma and lung squamous cell carcinoma

Cao

Wang

et al. 2021

Oncol Lett

View full text Add to dashboard Cite

The determination of biomarkers in the blood specific for lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) is crucial for the selection of effective treatment strategies and the prediction of prognosis. The purpose of the present study was to analyze the differentially expressed genes (DEGs) in LUSC and LUAD from The Cancer Genome Atlas (TCGA) database. In order to identify the potential biomarkers for non-small cell lung cancer (NSCLC) for clinical diagnosis, bioinformatics was used to analyze the DEGs of two subtypes of NSCLC, LUAD and LUSC. Exosomes were isolated from the serum of patients with LUAD or LUSC and identified using transmission electron microscopy, nanoparticle tracking analysis and western blot analysis. A total of four differential exosomal mRNAs were selected for validation with serum samples from 70 patients with NSCLC via reverse transcription-quantitative polymerase chain reaction. Receiver operating characteristic curves were established to evaluate the clinical diagnostic value of four DEGs for patients with LUAD and LUSC. The analysis based on TCGA data revealed the DEGs in LUSC and LUAD: A total of 1,619 genes were differentially expressed in patients with LUSC and LUAD. DEGs analyzed by Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses revealed that inflammation-related signaling pathways, such as complement pathways, and multiple autoimmune diseases, such as systemic lupus erythematosus and asthma were mainly enriched in LUAD. The cell cycle, Hippo signaling pathway, Rap1 signaling pathway and Wnt signaling pathway were the main signaling pathways enriched in LUSC. The combination of tumor protein P63 (TP63), keratin 5 (KRT5), CEA cell adhesion molecule 6 (CEACAM6) and surfactant protein B (SFTPB) improved the specificity and sensitivity in the diagnosis of different lung cancer subtypes. Exosomal TP63, KRT5, CEACAM6 and SFTPB mRNAs can thus be used as biomarkers to differentiate between LUSC and LUAD, and may provide a novel strategy for their differential diagnosis and treatment.

show abstract

Identification of differentially expressed genes in non-small cell lung cancer

Cited by 28 publications

References 39 publications

Risk Stratification in Acute Myeloid Leukemia Using CXCR Gene Signatures: A Bioinformatics Analysis

Risk Stratification in Acute Myeloid Leukemia Using CXCR Gene Signatures: A Bioinformatics Analysis

CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells

Use of four genes in exosomes as biomarkers for the identification of lung adenocarcinoma and lung squamous cell carcinoma

Contact Info

Product

Resources

About